Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors
Jerzy Lasota(National Institutes of Health), Markku Miettinen(National Institutes of Health), Maria Chosia(Pomeranian Medical University), Konrad Ptaszyński(Pomeranian Medical University), Sonja E. Steigen(UiT The Arctic University of Norway), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Janusz A. Siedlecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Bartosz Wasąg(Gdańsk Medical University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Ewa Kraszewska(Institute for Postgraduate Medical Education), Anna Jerzak vel Dobosz(The Maria Sklodowska-Curie National Research Institute of Oncology), Maarit Sarlomo‐Rikala(University of Helsinki), Regine Schneider‐Stock(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jerzy Stachura(Jagiellonian University), Gabriel Olabiyi Ogun(University of the Gambia), W. Ruka(Cleveland Clinic), Wanda Michej(European Organisation for Research and Treatment of Cancer)
Cited by 92
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Quality Indicators for Colonoscopy and the Risk of Interval Cancer
|New England Journal of Medicine|2010|2k